Bradley Pederson

Brad represents publicly traded companies, including technology, entertainment, and retail businesses. Brad offers expertise in capital markets, mergers and acquisitions, corporate finance, and corporate governance. With a diverse client base, Brad collaborates with businesses to create scalable business models and corporate structures to facilitate growth and capital acquisition. Additionally, he supports established businesses in raising capital through private and public offerings, driving organic growth, pursuing strategic acquisitions, and achieving successful exit events.

• Represented Sezzle Inc. (NASDAQ: SEZL) in its direct listing on the Nasdaq Capital Market and delisting from the Australian Securities Exchange (ASX).
• Represented issuers or underwriters in connection with six public follow-on equity offerings, multiple registered direct offerings (RDOs), and at-the-market offerings (ATMs).
• Represented Creative Realities, Inc. (NASDAQ: CREX) in its acquisitions of two competitors via public mergers and contemporaneous exempt and registered SEC financings.
• Represented Allied Esports International, Inc. and the World Poker Tour in a de-SPAC transaction with Black Ridge Acquisition Corp., now known as Allied Gaming & Entertainment, Inc. (NASDAQ: AGAE).
• Represented Allied Gaming & Entertainment, Inc. (NASDAQ: AGAE) in its sale of the World Poker Tour to Element Partners and its evaluation of an unsolicited sale proposal from Bally’s Corporation.
• Represented a publicly traded agricultural technology company in its strategic acquisitions, including the acquisitions of an engineering film company, an autonomous technology company, and a logistics software company.
• Represented a growing major American manufacturer and global supplier of bulk material processing and handling systems in all matters, including nine strategic acquisitions to expand its product base, brand offerings, and footprint in North America.
• Represented a publicly traded biopharmaceutical company in its sale to a Fortune 50 company of rights to our client’s drug candidate in North America in exchange for cash, plus earnout and milestone payments.
• Represented a publicly traded technology company in its acquisitions of two competitors via public mergers and contemporaneous exempt and registered SEC financings.